Liegeon G., Ngo-Giang-Huong Nicole, Salvadori N., Bunpo P., Cressey R., Achalapong J., Kanjanavikai P., Ayudhaya O. P. N., Prommas S., Siriwachirachai T., Sabsanong P., Mary J. Y., Jourdain Gonzague, Itap Study Team. (2022). Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus. Journal of Antimicrobial Chemotherapy, 77 (4), p. 1111-1118. ISSN 0305-7453.
Titre du document
Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus
Année de publication
2022
Auteurs
Liegeon G., Ngo-Giang-Huong Nicole, Salvadori N., Bunpo P., Cressey R., Achalapong J., Kanjanavikai P., Ayudhaya O. P. N., Prommas S., Siriwachirachai T., Sabsanong P., Mary J. Y., Jourdain Gonzague, Itap Study Team
Source
Journal of Antimicrobial Chemotherapy, 2022,
77 (4), p. 1111-1118 ISSN 0305-7453
Background Data evaluating the risk of proximal tubular dysfunction in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission (PMTCT) of HBV are scarce. Objectives To assess the risk of proximal tubulopathy in pregnant women receiving tenofovir disoproxil fumarate for PMTCT of HBV. Patients and methods We used urine samples collected from HBV monoinfected pregnant women who participated in a Phase III, multicentre, randomized, double-blind, placebo-controlled clinical trial assessing a tenofovir disoproxil fumarate short course from 28 weeks gestational age (28-wk-GA) to 2 months post-partum (2-months-PP) for PMTCT of HBV in Thailand. Markers of tubular dysfunction, including retinol binding protein, kidney injury molecule-1, alpha 1-microglobuin and beta 2-microglobulin, were assayed at 28- and 32-wk-GA and 2-months-PP visits. Proximal tubulopathy was defined as the presence of >= 2 of the following: tubular proteinuria, euglycaemic glycosuria and increased urinary phosphate. Results A total of 291 women participated in the study. No kidney-related adverse events were severe, and none led to tenofovir disoproxil fumarate discontinuation. At 2-months-PP, 3 of the 120 (3%) evaluated women in the tenofovir disoproxil fumarate group experienced proximal tubulopathy versus 3 of 125 (2%) in the placebo group (P = 1.00). None of the six women met the criteria for proximal tubulopathy at 12-months-PP but proteinuria persisted in three of them. No growth abnormalities were found at 1 year of age in infants born to mothers with proximal tubulopathy at 2-months-PP. Conclusions In these HBV-infected pregnant and breastfeeding women, tenofovir disoproxil fumarate administered from 28-wk-GA to 2-months-PP was not associated with a higher risk of proximal tubulopathy.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
THAILANDE
Localisation
Fonds IRD [F B010084594]
Identifiant IRD
fdi:010084594
